Investment Considerations VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on … Continue reading “VERAXA Biotech AG (NASDAQ: VRXA)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |